瑞銀:上調中國再保險(1508.HK)未來2-3年盈利預測 目標價升至1.1港元 維持“買入”評級
格隆匯7月27日丨瑞銀表示,中國再保險預料今年上半年税後純利增長55%至65%,主要推動力包括全球財險及意外險的定價提高。該行預計持續的定價上調將在未來兩至三年支撐中國再保險的盈利,將集團2021-2023財年的盈利預測上調2-3%,以反映其盈喜。該行還稱,中國再保險舉辦了投資者日介紹其數字戰略,該行相信,包括巨災模型等在內的創新技術舉措,將有助於集團實現更好的長期承保業績。瑞銀將中國再保險的目標價由1.09港元上調至1.1港元,以反映盈利預測的上調,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.